共查询到20条相似文献,搜索用时 140 毫秒
1.
目的探讨HBeAg阴性和阳性慢性乙型肝炎(CHB)患者组织病理学及免疫组化学的特点。方法对156例HBeAg阴性和阳性CHB患者肝组织炎症分级(G)及纤维化分期(S)的结果进行对比分析,并分别探讨两组CHB患者HBVDNA与ALT、G及S的关系,检测CHB患者肝组织HBsAg和HBcAg阳性表达率。结果HBeAg阴性CHB患者HBVDNA含量明显低于HBeAg阳性者,肝组织炎症程度高于后者,HBVDNA水平与ALT、G和S呈正相关,HBeAg阳性CHB血清HBVDNA与ALT、G无相关性。CHB患者肝组织HBcAg阳性率随炎症程度升高而升高。结论与HBeAg阳性CHB相比,HBeAg阴性者HBVDNA水平低,炎症程度高,HBVDNA水平与ALT、G、S正相关。CHB患者肝组织HBcAg阳性率随炎症程度增高而升高。 相似文献
2.
将67例慢性乙型肝炎(CHB)患者分为HBeAg阴性和阳性两组,检测两组血清ALT、AST、TBIL、A/G及HBV DNA定量;对血清HBV DNA定量与肝组织病理损伤进行相关性分析.发现HBeAg阴性组血清ALT水平升高较阳性组明显,阴性组HBV DNA定量水平低于阳性组,HBeAg阴性CHB肝组织病理损伤程度与血清HBVDNA定量呈正相关.认为HBeAg阴性CHB患者存在不同程度肝功能损害和病理损伤,其肝损伤原因除免疫攻击外,可能存在HBV直接损伤,应给予高度重视. 相似文献
3.
目的研究HBeAg阳性与HBeAg阴性慢性乙型肝炎合并脂肪肝患者临床和肝组织病理学特征。方法回顾性分析行肝穿刺活检术的慢性乙型肝炎(CHB)患者120例的临床资料,分析比较HBeAg阳性与HBeAg阴性CHB合并脂肪肝患者血清生化指标、病毒载量和肝组织病理学表现等的差异。结果在120例CHB患者中,HBeAg阳性68例(56.7%),阴性52例(43.3%)。在HBeAg阳性组中检出合并脂肪肝者11例(16.2%),明显低于HBeAg阴性组18例(34.6%,P〈0.05);HBeAg阳性合并脂肪肝患者血清TG和GGT水平高于无脂肪肝的HBeAg阳性患者(P〈0.05);在伴脂肪肝患者,HBeAg阳性者平均年龄(28.2±11.3岁)和纤维化评分(2.0±0.7)较HBeAg阴性者低(分别为36.2±14.6岁和2.6±0.8,P〈0.05),而体重指数(BMI,27.3±4.0)、TG(3.7±0.4mmol/L)和HBV DNA定量水平(6.8±1.3 lgcopies/mL)高于阴性患者(分别为20.1±5.1,1.5±0.4 mmol/L,4.4±2.6 lgcopies/mL),差异有统计学意义(P〈0.05)。结论 HBeAg阴性慢性乙型肝炎合并脂肪肝患者比例较高,应尽早行肝穿刺活检,以便指导治疗。 相似文献
4.
目的 分析HBeAg阴性与阳性慢性乙型肝炎(CHB)患者临床和肝组织病理学特点,探讨影响CHB患者发生明显肝纤维化的危险因素。方法 回顾性分析250例CHB患者血清HBV DNA水平、Fibroscan检测肝脏硬度(stiffness)值和肝穿刺组织病理学特点,应用多因素Logistic回归模型分析影响CHB患者发生明显肝纤维化的独立危险因素。结果 160例HBeAg阴性患者血清HBV DNA ≥1×105 copies/ml者所占比例显著低于HBeAg阳性组(66.9%对99.4%,P<0.05);HBeAg阴性组血清ALT和AST水平显著低于HBeAg阳性组(P<0.05);血清HBeAg阴性组与阳性组肝组织炎症分级和纤维化分期总体分布差异无统计学意义(P>0.05);多因素Logistic回归分析结果显示年龄≥40岁、HBV DNA水平高、PTA低和Stiffness水平高为CHB患者存在明显肝纤维化的独立危险因素。结论 血清HBeAg阴性与阳性CHB患者存在一些临床和肝组织病理学特征的差异,血清HBeAg阴性患者可能存在更为严重的临床和预后问题,需要给予特别的关注和管理。 相似文献
5.
目的研究DNA芯片技术在检测乙型肝炎和肝硬化患者肝组织及血清中HBVDNA的应用,并与雅培试剂、免疫组织化学和原位分子杂交法比较。方法用点样仪将PCR扩增的HBVDNA探针制成基因芯片。对15例慢性乙型肝炎(下称慢乙肝)患者的血清及肝活检组织、99例乙型肝炎后肝硬化肝组织,分别用基因芯片、原位分子杂交法、免疫组织化学法、雅培试剂检测HBVDNA、HBcAg、HBsAg、HBeAg。结果15例慢乙肝HBsAg、HBeAg阳性患者的乙型肝炎血清基因芯片检测均阳性。15例肝组织标本中,免疫组化法HBcAg阳性15例,HBVDNA原位分子杂交阳性14例。基因芯片检测阳性14例。99例乙型肝炎后肝硬化肝组织标本中,HBcAg阳性67例、HBVDNA阳性53例,基因芯片检测阳性46例;32例HBcAg、HBVDNA阴性组织基因芯片检测均阴性。结论肝炎基因诊断芯片可以检测肝组织及血清HBVDNA,其诊断准确率高,假阳性率低。 相似文献
6.
目的探讨HBeAg阳性与HBeAg阴性慢性乙型肝炎(CHB)患者停用核苷(酸)类似物(NUC)抗病毒治疗后肝炎复发致HBV相关慢加急性肝衰竭(HBV-ACLF)的临床病情转归的差异及可能的原因。方法选取2017年1月—2018年12月于南昌大学第一附属医院收治的108例停用NUC后致HBV-ACLF的CHB患者。根据HBeAg状态分为HBeAg阳性组(n=57)和HBeAg阴性组(n=51),分析比较两组患者性别、年龄、临床表现、体征和入院时TBil、DBil、ALT、AST、PT、活化部分PT(APTT)、PT/INR、HBV DNA定量检测结果,以及并发症(肝性脑病、肝肾综合征、自发性腹膜炎等)情况、HBV-ACLF病情转归差异。同时,选取48例持续NUC抗病毒治疗>2年且HBV DNA<20 IU/mL的CHB患者,收集并检测其血清HBV pgRNA水平,探讨影响停药时不同HBeAg状态患者HBV-ACLF预后差异的可能原因。符合正态分布的计量资料两组间比较采用两独立样本t检验;不符合正态分布的计量资料两组间比较采用Kruskal-Wallis H检验。计数资料两组间... 相似文献
7.
目的 研究慢性乙型肝炎(CHB)患者(1×ULN≤ALT≤2×ULN)肝组织学与血清学的关系.方法 对全国多中心516例CHB患者(1×ULN≤ALT≤2×ULN)行血清学及肝穿刺病理检查,依据血清HBeAg表达水平将患者分为HBeAg阳性组和HBeAg阴性组,分析两组肝组织病理学与血清学指标的相关性.结果 HBeAg阳性患者肝组织炎症分级和肝纤维化分期与血清HBsAg和HBeAg表达水平呈负相关(P<0.01),与血清透明质酸(HA)和α2-巨球蛋白水平呈正相关(P<0.01),与血清HBVDNA水平无明显相关性;HBeAg阴性患者肝组织炎症分级和肝纤维化分期与血清HBV DNA水平呈正相关(P<0.01),与HBsAg、HA和α2-巨球蛋白等无明显相关性.结论 血清HBV DNA可做为HBeAg阴性CHB患者肝脏病变程度的有效预测指标,HBsAg、HBeAg、HA和α2-巨球蛋白均可做为HBeAg阳性CHB患者肝组织损伤的预测指标. 相似文献
8.
目的研究HBeAg阴性和阳性慢性乙型肝炎(以下简称慢乙肝)患者血清HBVDNA定量与肝组织炎症活动度及纤维化程度的关系。方法选取慢乙肝患者68例,行肝穿刺病理检查,并检测血清HBVDNA定量,按照HBeAg阴性和阳性分组,进行相关性检验。结果HBeAg阴性患者血清HBVDNA定量与肝组织炎症活动度及纤维化程度之间呈明显正相关,r分别为0.706、0.689,P均小于0.05;HBeAg阳性者血清HBVDNA定量与肝组织炎症活动度及纤维化程度之间均无相关性,r分别为-0.119、-0.096,P均大于0.05。结论血清HBVDNA定量可作为HBeAg阴性慢乙肝患者肝组织损伤程度的预测指标之一。 相似文献
9.
乙型肝炎肝硬化患者HBV血清学模式与病毒载量关系的研究 总被引:2,自引:0,他引:2
目的通过分析乙型肝炎肝硬化患者HBV血清学模式、HBVDNA、肝功能,探讨乙型肝炎肝硬化患者抗病毒治疗的临床意义。方法回顾性分析168例乙型肝炎肝硬化患者的病史、血清病毒学指标、肝功能,按不同的指标进行分组、比较。结果168例乙型肝炎肝硬化患者中以HBVDNA阳性者占绝大多数(91.0%),其中HBeAg阴性者占81.0%;分组比较提示HBVDNA阳性组ALT、AST显著高于阴性组,ALT异常组HBVDNA载量明显高于ALT正常组(P〈0.01);不同Child—Push分级之间HBVDNA载量无显著性差异。结论乙型肝炎肝硬化住院患者以HBVDNA阳性及HBeAg阴性者居多,HBVDNA呈较高水平复制者,肝脏炎症损害亦较重,故应及早予以抗病毒治疗。 相似文献
10.
不同类型慢性乙型肝炎血清HBV DNA基因含量与临床的关系 总被引:2,自引:1,他引:2
探讨不同类型慢性乙型肝炎 (慢乙肝 )患者病毒复制水平与肝损害程度的关系。 180例慢乙肝患者血清HBVDNA基因含量采用荧光定量PCR方法检测。血清HBeAg阳性组HBVDNA含量 (10 6 3 5± 1 84)显著高于HBeAg阴性组 (10 4 73± 1 88) (P <0 0 1) ,不同类型慢乙肝组血清HBVDNA含量相比较无显著性差异 (P >0 0 5 )。研究证实 ,血清HBeAg的存在影响HBVDNA的水平变化 ,不同类型慢性乙型肝炎肝损害程度与血清HBVDNA基因含量无明显关系 相似文献
11.
乙型肝炎e抗原阴性慢性乙型肝炎和肝硬化患者病毒基因型及丙氨酸氨基转移酶水平分析 总被引:9,自引:0,他引:9
目的观察乙型肝炎e抗原(HBeAg)阴性慢性乙型肝炎(CHB)及肝硬化患者的乙型肝炎病毒(HBV)基因型及丙氨酸氨基转移酶(ALT)水平。方法采用酶联免疫吸附法检测62例CHB和41例肝硬化患者HBV标志物和血清ALT水平,用聚合酶链反应法检测其HBV基因型。结果CHB患者中,21 例(33.9%)为HBeAg阴性,41例(66.1%)为HBeAg阳性;肝硬化患者中,28例(68.3%)为HBeAg阴性,13例(31.7%)为HBeAg阳性。CHB患者中,53例(85.5%)为C基因型,9例(14.5%)为B基因型; 肝硬化患者中39例(95.1%)为C基因型,2例(4.9%)为B基因型。HBeAg阴性CHB患者ALT>40 U/L 者的比例低于HBeAg阳性组(分别为47.6%和85.4%),差异有统计学意义(P<0.01)。HBeAg阴性肝硬化患者ALT>40 U/L者的比例低于HBeAg阳性组(分别为64.3%和92.3%)但差异无统计学意义。结论CHB 和肝硬化患者中,HBeAg阴性者的比例较高,此类患者的ALT水平较低,以C基因型占优势。 相似文献
12.
目的探讨HBeAg(+)和HBeAg(-)慢性乙型肝炎患者外周血HBsAg与HBV DNA的关系。方法定量检测HBeAg(+)55例和HBeAg(-)36例慢性乙型肝炎患者血清HbsAg和HBV DNA的水平。结果 HBeAg(+)患者血清HBV DNA、ALT和AST水平较HBeAg(-)患者高(P〈0.05);HBeAg(+)患者血清HBsAg水平较HBeAg(-)患者低(P〈0.05);高水平血清HbsAg患者血清HBV DNA水平低(F=10.096,P〈0.01);HBeAg(+)慢性乙型肝炎患者HBsAg与HBV DNA存在负相关(r=-0.796,P〈0.01),而HBeAg(-)慢性乙型肝炎患者HBsAg与HBV DNA无相关性(r=0.289,P〉0.05)。结论定量检测慢性乙型肝炎患者血清HBsAg水平有一定的临床意义。 相似文献
13.
Significance of hepatitis B core antigen in the liver in patients with chronic hepatitis B and its relation to hepatitis B virus DNA 总被引:1,自引:0,他引:1
JAE YOUNG YOO HAK YANG KIM CHOONG KEE PARK SHIN KWANG KHANG JIN WU JEONG WHAN KOOK CHUNG ADRIAN M. DIBISCEGLIE JAY H. HOOFNAGLE 《Journal of gastroenterology and hepatology》1990,5(3):239-243
Liver biopsies from 52 patients with chronic hepatitis B were investigated for the presence and distribution of HBcAg and the results were compared with the status of hepatitis B virus deoxyribonucleic acid (HBV-DNA). The patients consisted of 37 men and 15 women, aged 16-55 years (mean = 34 years). Serum alanine aminotransferase (ALT) was elevated in 50 patients (range: 18-969 U/L; mean = 290 U/L). Serological testing showed HBsAg in all, HBeAg in 45 (87%), and HBV-DNA in 28 (54%). Liver biopsies demonstrated HBcAg in 35 (67%) patients. HBcAg was not only present in 31 of 45 (69%) patients who were seropositive for HBeAg, but also in four of seven (57%) with antibody to HBeAg (anti-HBe). In 28 of 35 (80%) patients with HBcAg in the liver, serum HBV-DNA was detected. However, no serum HBV-DNA was detected in 17 patients who had no detectable HBcAg in the liver. The distribution of HBcAg in the liver was rather cytoplasmic and nuclear than nuclear alone. Among 33 patients with cytoplasmic HBcAg in the liver, 15 (45%) had an evidence of acute exacerbation of hepatitis with marked ALT elevation (range: 168-894 U/L; mean = 385 U/L) and nine patients showed severe chronic active hepatitis and confluent necrosis, histologically. These results indicate that the presence of HBcAg in the liver correlates with the amount of circulating hepatitis B virus as quantified by serum level of HBV-DNA. The predominant cytoplasmic HBcAg in the liver may suggest the possibility of multiple episodes of acute exacerbation and more severe ongoing hepatitis during the clinical course. 相似文献
14.
目的探讨ALT、HBV DNA以及血清纤维化标志物透明质酸(HA)、层粘连蛋白(LN)、Ⅲ型前胶原肽(PⅢP)、Ⅳ型胶原(CⅣ)与慢性乙型肝炎肝纤维化程度的关系。方法检测281例慢性乙型肝炎患者血清中ALT、HBV DNA和纤维化标志物(HA、LN、PⅢP及CⅣ)的水平,并行肝活检检测肝组织病理纤维化分期。结果 HBeAg阴性慢性乙型肝炎患者HBV DNA水平较低、纤维化程度较高。HBeAg阳性患者纤维化程度与HBV DNA呈负相关(r=-0.251,P<0.001),S≥3组水平最低。慢性乙型肝炎患者纤维化程度与PⅢP水平呈正相关,其水平随着纤维化程度的加重而明显升高。结论 PⅢP水平可能作为评估慢性乙型肝炎患者肝纤维化程度的血清学指标,血清HBV DNA与肝脏纤维化严重程度的关系仍需进一步深入探讨。 相似文献
15.
Circulating IL-2, IL-10 and TNF-alpha in chronic hepatitis B: their relations to HBeAg status and the activity of liver disease 总被引:21,自引:0,他引:21
Bozkaya H Bozdayi M Türkyilmaz R Sarioglu M Cetinkaya H Cinar K Köse K Yurdaydin C Uzunalimoglu O 《Hepato-gastroenterology》2000,47(36):1675-1679
BACKGROUND/AIMS: Preferential production of immunoregulatory cytokines may play an important role in the pathogenesis of chronic hepatitis B. We aimed to determine the serum levels of IL-2, IL-10 and TNF-alpha in patients with chronic hepatitis B and to correlate these findings with the activity of liver disease, HBeAg/anti-HBe status and replication level of the virus. METHODOLOGY: Seventy-two chronic hepatitis B patients were categorized into 4 groups according to activity of liver disease and HBeAg status. Group 1 (n = 13): HBeAg and HBV DNA-positive with persistently normal ALT. Group 2 (n = 20): HBeAg and HBV DNA-positive patients with persistently elevated ALT. Group 3 (n = 19): HBeAg and HBV DNA-negative patients with persistently normal ALT. Group 4 (n = 20): HBeAg-negative patients with persistently elevated ALT and variable serum HBV DNA. IL-2, IL-10 and TNFa levels were determined in stored patient sera. RESULTS: Apart from group 1 patients, all patients groups had higher IL-2 levels compared to controls suggesting that IL-2 production is increased when liver disease becomes active in HBeAg-positive phase of HBV infection. Only group 2 patients had elevated IL-10 levels compared to controls. None of the HBeAg-negative patients had detectable TNF-alpha levels while 64% HBeAg-positive patients had elevated levels of TNF-alpha irrespective of the activity of liver disease. Except TNF-alpha, no association was found between HBV DNA status and the presence or absence of detectable cytokines in circulation. CONCLUSIONS: Our results suggest that circulating cytokine profile in chronic hepatitis B is related with the HBeAg status, replication level of the virus and the activity of liver disease. 相似文献
16.
Serum soluble interleukin-2 receptor levels in patients with chronic hepatitis B virus infection and its relation with anti-HBc 总被引:2,自引:0,他引:2
AIM:To investigate the relationship between serumsoluble interleukin-2 receptor(sIL-2R)level and anti-HBcin patients with chronic hepatitis B virus(HBV)infection.METHODS:Sera from 100 patients with chronic HBVinfection and 30 healthy controls were included in thisstudy.The patients were divided into group A[HBsAg( ),HBeAg( )and anti-HBc( ),n=50]and group B[HBsAg( ),HBeAg( )and anti-HBc(-),n=50].sIL-2R levelswere determined using ELISA.HBV DNA and alanineaminotransferase(ALT)were also detected.RESULTS:Serum sIL-2R levels were significantly higherin patients with chronic HBV infection than in healthycontrols.Moreover,serum sIL-2R levels were significantlyhigher in patients with HBsAg( ),HBeAg( )and anti-HBc( )(976.56±213.51×10~3 U/L)than in patients withHBsAg( ),HBeAg( )and anti-HBc(-)(393.41±189.54×10~3 U/L,P<0.01).A significant relationship was foundbetween serum sIL-2R and ALT levels(P<0.01)inpatients with chronic HBV infection,but there was nocorrelation between sIL-2R and HBV DNA levels.Theanti-HBc status was significantly related to the age ofpatients(P<0.01).CONCLUSION:The high sIL-2R level is related topositive anti-HBc in chronic hepatitis B patients.Positiveanti-HBc may be related to T-lymphocyte activation andnegative anti-HBc may imply immune tolerance in thesepatients. 相似文献
17.
Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: results after 3 years of therapy 总被引:82,自引:0,他引:82
Leung NW Lai CL Chang TT Guan R Lee CM Ng KY Lim SG Wu PC Dent JC Edmundson S Condreay LD Chien RN;Asia Hepatitis Lamivudine Study Group 《Hepatology (Baltimore, Md.)》2001,33(6):1527-1532
A study in Chinese patients with chronic hepatitis B showed that treatment with lamivudine for 1 year significantly improves liver histology and enhances hepatitis B e antigen (HBeAg) seroconversion compared with placebo. Fifty-eight patients from this 1-year study have received long-term treatment with lamivudine 100 mg; the outcome of 3 years of lamivudine is reported here. Before treatment, all patients had detectable HBeAg. HBeAg seroconversion (HBeAg-negative, anti-HBe-positive), hepatitis B virus (HBV)-DNA suppression, alanine transaminase (ALT) normalization, emergence of YMDD variant HBV, liver histology, and long-term safety were assessed. After 3 years of continuous treatment with lamivudine 100 mg daily, 40% (23 of 58) of patients achieved HBeAg seroconversion. In patients with baseline serum ALT >2 x upper limit of normal (ULN), the rate of HBeAg seroconversion was 65% (17 of 26). Median serum HBV-DNA concentrations were below the level of detection, and median ALT concentrations were within the normal range throughout 3 years of treatment. YMDD variant HBV emerged in 33 of 58 (57%) patients during the 3 years, of whom 9 (27%) achieved HBeAg seroconversion (6 after emergence of YMDD variant HBV). ALT levels and histologic scores after emergence of YMDD variant HBV did not show major deterioration. Lamivudine was well tolerated during 3 years of therapy. In conclusion, these data in Chinese patients with chronic hepatitis B show enhanced seroconversion rates with extended lamivudine treatment. Up to two thirds of patients with moderately elevated pretreatment ALT achieved HBeAg seroconversion after 3 years of therapy. 相似文献
18.
Rate of YMDD motif mutants in lamivudine-untreated Iranian patients with chronic hepatitis B virus infection. 总被引:1,自引:0,他引:1
Amitis Ramezani Ali Akbar Velayati Mohammad Reza Hasanjani Roshan Latif Gachkar Mohammad Banifazl Hossein Keyvani Arezoo Aghakhani 《International journal of infectious diseases》2008,12(3):252-255
BACKGROUND: Lamivudine is used for the treatment of chronic hepatitis B patients. Recent studies show that the YMDD motif mutants (resistant hepatitis B virus) occur as natural genome variability in lamivudine-untreated chronic hepatitis B patients. In this study we aimed to determine the rate of YMDD motif mutants in lamivudine-untreated chronic hepatitis B patients in Iran. PATIENTS AND METHODS: A total of 77 chronic hepatitis B patients who had not been treated with lamivudine were included in the study. Serum samples from patients were tested by polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) for detection of YMDD motif mutants. All patients were also tested for liver enzymes, anti-HCV, HBeAg, and anti-HBe. RESULTS: Of the 77 patients enrolled in the study, 73% were male and 27% were female. Mean ALT and AST levels were 124.4+/-73.4 and 103.1+/-81 IU/l, respectively. HBeAg was positive in 40% and anti-HBe in 60% of the patients. Anti-HCV was negative in all of them. YMDD motif mutants were not detected in any of the patients despite the liver enzyme levels and the presence of HBeAg or anti-HBe. CONCLUSION: Although the natural occurrence of YMDD motif mutants in lamivudine-untreated patients with chronic hepatitis B has been reported, these mutants were not detected in Iranian lamivudine-untreated chronic hepatitis B patients. 相似文献
19.
目的 探讨拉米夫定治疗慢性乙型肝炎患者的疗效影响因素,并初步评价基线特征、24周早期病毒学应答及治疗方案对疗效和病毒学突破(VB)发生率的影响.方法 对接受拉米夫定治疗的233例慢性乙型肝炎患者(其中90例治疗期间加用或换用阿德福韦酯)的专科门诊病历资料进行回顾性分析,采用聚合酶链反应法、酶联免疫吸附法分别检测HBV DNA水平与HBsAg、抗-HBs,HBeAg,抗-HBe水平.用SPSS17.0统计软件通过Kaplan-Meier法描述生存时间分布,并分析基线HBV DNA水平,HBeAg状态、ALT水平和疗效的关系.计量资料用t检验分析,计数资料用x2检验.结果 HBeAg阳性与HBeAg阴性患者HBV DNA阴转率分别为63.4%和84.6%,ALT复常率分别为83.8%和81.3%,VB发生率分别为31.0%和14.3%;60.6%的HBeAg阳性患者出现HBeAg阴转,28.9%出现HBeAg/抗-HBe血清学转换.HBeAg阳性患者中,与基线ALT<2.5×正常值上限(ULN)者比较,≥2.5×ULN者HBV DNA阴转率无明显变化(P>0.05),而HBeAg阴转率(66.7%与45.0%)和HBeAg血清学转换率(33.3%与17.5%)明显升高(P值均<0.05),VB发生率则明显下降(34.3%与50.0%,P<0.05),基线HBV DNA<1×106拷贝/ml者VB发生率为23.4%,与HBV DNA≥1×106拷贝/ml者的46.3%比较,差异有统计学意义(P<0.05).HBeAg阳性患者24周有初始病毒学应答(IVR)者的HBV DNA阴转率(76.3%与45.5%)、HBeAg阴转率(72.4%与43.9%)和HBeAg血清学转换率(40.8%与12.1%)均明显高于无IVR者(P值均<0.01),VB发生率较低(28.9%与45.5%,P<0.05).出现VB后,与单一拉米夫定组比较,加药或换药组中HBeAg阳性者HBV DNA阴转率(40.6%与16.7%)、HBeAg血清学转换率(21.9%与0)较高,HBeAg阴转率(37.5%与41.7%)较低,ALT复常率无差别(均为75%);而HBeAg阴性患者的HBV DNA阴转率、ALT复常率较高.结论 拉米夫定抗病毒疗效确切,基线ALT≥2.5×ULN和(或)HBV DNA水平<1×106拷贝/ml的患者疗效较好,VB发生率较低,24周IVR对拉米夫定疗效有预测价值;出现VB后,加用或者换用阿德福韦酯比继续单用拉米夫定治疗的效果好. 相似文献
20.
Profile of hepatitis B e antigen-negative chronic hepatitis B. 总被引:2,自引:0,他引:2
D N Amarapurkar R Baijal P P Kulshrestha S Agal M R Chakraborty S S Pramanik 《Indian journal of gastroenterology》2002,21(3):99-101
BACKGROUND: Although chronic hepatitis B occurs in hepatitis B e antigen (HBeAg)-negative patients, its prevalence and clinical significance are not known. AIM: To determine the prevalence and profile of HBeAg-negative chronic hepatitis B virus (HBV) infection. METHODS: A retrospective analysis of 363 consecutive patients (mean age 36 y; 288 men) with chronic HBV infection was performed. All patients were HBsAg-positive. Tests for liver profile, HBeAg and anti-HBe antibody were performed in all patients. Serum HBV DNA was tested using branched DNA assay in 245 patients. The patients were classified into three groups: no cirrhosis with normal ALT levels, no cirrhosis with elevated ALT levels, and clinical or histological evidence of cirrhosis. RESULTS: Of 363 patients, 141 (39%) were HBeAg-positive and 222 (61%) HBeAg-negative. Of HBeAg-negative patients, 120 (54%) had normal ALT, 45 (20%) had elevated ALT and 57 (26%) had evidence of cirrhosis; corresponding figures in the HBeAg-positive patients were 40 (28%), 66 (47%) and 35 (25%). HBV DNA was positive in 53 of 131 (40%) HBeAg-negative patients tested; of these 53 patients, 9 (17%) had normal ALT, 20 (38%) had elevated ALT and 24 (45%) had cirrhosis. Thus, 72% of HBeAg-positive and 46% of HBeAg-negative patients had elevated ALT and/or cirrhosis. Among the latter group, 83% of HBV DNA-positive patients had elevated ALT and/or cirrhosis. Overall, 18% of HBsAg-positive patients had HBeAg-negative, HBV DNA-positive liver disease. CONCLUSION: HBeAg-negative chronic hepatitis B is not an uncommon and benign entity and chronic liver disease develops in a significant proportion of such patients. 相似文献